(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.82% $ 7.05
Live Chart Being Loaded With Signals
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...
Stats | |
---|---|
Tagesvolumen | 892.00 |
Durchschnittsvolumen | 5 243.00 |
Marktkapitalisierung | 1.65B |
EPS | $0 ( 2024-03-07 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-05-14 |
Last Dividend | $0.593 ( 2020-03-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | 7.66 |
ATR14 | $0 (0.00%) |
Bavarian Nordic A/S Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Bavarian Nordic A/S Finanzdaten
Annual | 2023 |
Umsatz: | $7.06B |
Bruttogewinn: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
Umsatz: | $7.06B |
Bruttogewinn: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Umsatz: | $3.15B |
Bruttogewinn: | $1.70B (53.99 %) |
EPS: | $-4.93 |
Financial Reports:
No articles found.
Bavarian Nordic A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.593 | 2020-03-27 |
Last Dividend | $0.593 | 2020-03-27 |
Next Dividend | $0 | N/A |
Payout Date | 2020-04-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.593 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.27 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SWRAY | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
HNFSA | Ex Dividend Junior | 2023-08-09 | Quarterly | 0 | 0.00% | |
ATDRY | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
OSCUF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
DQJCF | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
TSGTY | Ex Dividend Knight | 2023-06-23 | Annually | 0 | 0.00% | |
JDVB | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
BMBN | Ex Dividend Knight | 2023-06-30 | Semi-Annually | 0 | 0.00% | |
RCBC | Ex Dividend Junior | 2023-07-31 | Quarterly | 0 | 0.00% | |
FABP | Ex Dividend Knight | 2023-07-31 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.209 | 1.500 | 5.82 | 8.74 | [0 - 0.5] |
returnOnAssetsTTM | 0.103 | 1.200 | 6.57 | 7.89 | [0 - 0.3] |
returnOnEquityTTM | 0.153 | 1.500 | 9.41 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.938 | 0.800 | 5.31 | 4.25 | [1 - 3] |
quickRatioTTM | 1.342 | 0.800 | 6.81 | 5.45 | [0.8 - 2.5] |
cashRatioTTM | 0.530 | 1.500 | 8.17 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00430 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.16 | 1.000 | 1.793 | 1.793 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.08 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00597 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.652 | 1.000 | 2.47 | 2.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.215 | 1.000 | 7.70 | 7.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 18.15 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.492 | 0.800 | -0.0521 | -0.0416 | [0.5 - 2] |
Total Score | 10.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 2.55 | 1.000 | 9.84 | 0 | [1 - 100] |
returnOnEquityTTM | 0.153 | 2.50 | 9.62 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00228 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.158 | 1.000 | 8.54 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.